Recombinant Human TIGIT Protein (aa 1-138, His Tag)(Active)
SKU: PKSH031356-500
Recombinant Human TIGIT Protein (aa 1-138, His Tag)(Active)
SKU # | PKSH031356 |
Expression Host | HEK293 Cells |
Description
Synonyms | T-cell immunoreceptor with Ig and ITIM domains, TIGIT, V-set and immunoglobulin domain-containing protein 9, V-set and transmembrane domain-containing protein 3, VSIG9, VSTM3 |
Species | Human |
Expression Host | HEK293 Cells |
Sequence | Met 1-Phe 138 |
Accession | Q495A1 |
Calculated Molecular Weight | 14.2 kDa |
Tag | C-His |
Bio-activity | Measured by its ability to bind with human CD155-Fc in a functional ELISA. Measured by its ability to bind with mouse PVR-Fch in a functional ELISA. |
Properties
Purity | > 85 % as determined by reducing SDS-PAGE. |
Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
Formulation | Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
Reconstitution | Please refer to the printed manual for detailed information. |
Background
TIGIT; also known as V-set and transmembrane domain-containing protein 3 (VSTM3) or V-set and immunoglobulin domain-containing protein 9 (VSIG9) is a new surface protein containing an immunoglobulin variable domain; a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on regulatory; memory; activated T cells and NK cells. It binds PVR with high affinity; and PVRL2 with lower affinity; but not PVRL3. Knockdown of TIGIT with siRNA in human memory T cells did not affect T cell responses; however; TIGIT inhibits NK cytotoxicity directly through its ITIM. TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. The binding of PVR to TIGIT on human dendritic cells enhanced the production of IL-10 and diminished the production of IL-12p40. In addition; TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition.